Medical Condition News

RSS

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

GE Healthcare Medical Diagnostics today announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. The safety and efficacy of Optison with exercise stress or pharmacologic stress testing have not been established.

12 Jul 2010

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.

12 Jul 2010

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Biodel Inc. announced today the award of two research grants by the Juvenile Diabetes Research Foundation to Stanford University and Oregon Health & Science University to evaluate the use of VIAject (ultra-rapid-acting injectable human insulin) in the treatment of diabetes.

12 Jul 2010

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Reata Pharmaceuticals, Inc. has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.

12 Jul 2010

Study results show cognitive decline significantly lower among regular tea drinkers

Results of a new study found people age 65 or older who drank tea regularly had 17-37% less cognitive decline compared with people who did not drink tea. The new findings were presented here at the Alzheimer's Association's International Conference on Alzheimer's Disease 2010.

12 Jul 2010

Bayer HealthCare announces over $2.5M for largest awards program in hemophilia

Bayer HealthCare announced today that it awarded more than $2.5 million in funding to 19 recipients from 10 countries through its Bayer Hemophilia Awards Program (BHAP). BHAP is the largest awards program of its kind in hemophilia, providing funds that support clinical and basic research, encourage new physicians to enter the field and enable continuing education for caregivers around the world.

12 Jul 2010

Researchers investigate impact of flavonols on stroke risk

New research has found that people who consume relatively high amounts of flavonols have a lower risk of stroke. Tea was most likely the major contributor of flavonols in the diet, ranging from 30 percent (US) to 70 percent (the Netherlands) of the total intake.

12 Jul 2010

Survey shows only few Canadians identify painful physical symptoms of depression

Although the majority of Canadians believe in a mind/body connection, agreeing how they feel physically is related to how they feel emotionally (87 per cent), only half make the link when it comes to depression.

12 Jul 2010

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases. The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD), and pulmonary embolism, independent of other known risk factors.

12 Jul 2010

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.

12 Jul 2010

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

AngioDynamics announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex® port technology - to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT).

12 Jul 2010

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

12 Jul 2010

Alzheimer's Association launches Internet and phone-based clinical trial matching service

The Alzheimer's Association announced today the launch of Alzheimer's Association TrialMatch(TM), a confidential and free interactive tool that provides comprehensive clinical trial information and an individualized trial matching service for people with Alzheimer's disease and related dementias. The Internet (www.alz.org/trialmatch) and phone-based (800-272-3900) service debuted during the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI.

12 Jul 2010

New website presenting latest in Alzheimer's disease research unveiled at AAICAD 2010

A new website showcasing the latest in Alzheimer's disease research and science - www.alz.org/research - is being unveiled at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu.

12 Jul 2010

New approach of screening drugs that encourage stem cells to repair damaged tissue

Professor Fiona Watt will today (12 July) give the Anne McLaren Memorial Lecture at the UK National Stem Cell Network annual science meeting and will detail a new approach to screening for drugs that target stem cells. To begin with, this is being developed for adult skin stem cells, giving hope for new drugs to promote wound healing and aid the use of stem cells to, for example, treat severe burns. This technique can also be applied to a wide range of stem cells, opening up the possibilities for harnessing stem cells in regenerative medicine.

12 Jul 2010

BCAN to celebrate first annual Bladder Cancer Awareness Day

The Bladder Cancer Advocacy Network will celebrate the first annual Bladder Cancer Awareness Day on Saturday, July 17 with more than two dozen volunteer-led events nationwide. In addition to raising public awareness about the risks and signs of bladder cancer, the events will serve as a forum for bladder cancer patients, survivors and their caregivers to meet and share their stories.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.

12 Jul 2010

Addition of fat to mouse stem cells push them to develop into subcutaneous or visceral fat storage cells

New research being presented today (12 July) at the UK National Stem Cell Network Annual Science Meeting in Nottingham shows that adding fat to mouse stem cells grown in the lab affects their response to the signals that push them to develop into one or other of the main types of fat storage cells - subcutaneous (under the skin) or visceral (around the organs).

12 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Medical Condition News

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

Stanford University, OHSU receive grants to study VIAject for treating patients with diabetes

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Study results show cognitive decline significantly lower among regular tea drinkers

Bayer HealthCare announces over $2.5M for largest awards program in hemophilia

Researchers investigate impact of flavonols on stroke risk

Survey shows only few Canadians identify painful physical symptoms of depression

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Alzheimer's Association launches Internet and phone-based clinical trial matching service

New website presenting latest in Alzheimer's disease research unveiled at AAICAD 2010

New approach of screening drugs that encourage stem cells to repair damaged tissue

BCAN to celebrate first annual Bladder Cancer Awareness Day

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Addition of fat to mouse stem cells push them to develop into subcutaneous or visceral fat storage cells

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News